文献速递神经免疫

绝经对多发性硬化残疾进展的影响

Menopause Impact on Multiple Sclerosis Disability Progression.
PubMed 文献 · JAMA Neurol · 2025-01-01

这项基于MSBase注册库的回顾性队列研究纳入987名复发起病型MS女性,分析绝经(作为时变协变量)与6个月确认残疾进展(CDP)及继发进展型MS(SPMS)风险的关系。多变量调整后,绝经与CDP(HR 0.95;95%CI 0.70-1.29;P=0.70)和SPMS(HR 1.00;95%CI 0.60-1.67;P=1.00)风险均无显著关联。二次分析中绝经亦非EDSS恶化的拐点。

要点

  • 绝经未增加复发起病型MS女性的6个月确认残疾进展风险。
  • 绝经与继发进展型MS风险无显著关联。
  • 绝经不是EDSS恶化的拐点,不支持其作为老年MS女性残疾进展的主因。

核心结论

  • 绝经与复发起病型MS女性的残疾进展风险增加无关。
  • 结果不支持绝经是老年MS女性残疾进展的主要因素。

研究设计与样本

  • 回顾性队列研究,使用MSBase注册库前瞻性临床数据,提取于2023年7月1日。
  • 主分析纳入987名复发起病型MS女性,至少3次EDSS测量且报告绝经状态。
  • 二次分析纳入209名在绝经前后均有EDSS测量的女性。

主要发现

  • 主分析包括583名绝经前和404名绝经后女性,绝经中位年龄48.5岁。
  • 多变量调整后,绝经与CDP风险无关(HR 0.95;95%CI 0.70-1.29;P=0.70)。
  • 绝经与SPMS风险无关(HR 1.00;95%CI 0.60-1.67;P=1.00)。
  • 二次分析中,多变量调整后绝经不是EDSS恶化的拐点。

临床怎么用

  • 对于复发起病型MS女性,绝经不应当被视为残疾进展的独立危险因素。
  • MS女性围绝经期的残疾进展需结合其他因素综合评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Most women with multiple sclerosis (MS) will experience menopause while living with MS. Despite this, the impact of menopause on MS disease trajectory remains unclear. OBJECTIVE: To assess whether menopause modifies the risk of disability progression for women with relapse-onset MS. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used prospective clinical data that were collected within the MSBase Registry. Data were extracted from MSBase on July 1, 2023. These data were analyzed from January 2023 through February 2025. Female participants were recruited from 8 Australian neuroimmunology specialist centers (1 private practice and 7 tertiary referral centers) from 2018 through 2021. Participants included 1468 women aged 18 years or older who completed dedicated retrospective women's health surveys. Of these, 987 women with relapse-onset MS, 3 or more Expanded Disability Status Scale (EDSS) measurements recorded, and reported menopausal status were included in the primary analysis. The secondary analysis included 209 women with 1 or more EDSS measurements recorded in the MSBase database predate and postdate of menopause onset. EXPOSURE: Crude and adjusted Cox proportional hazards models were used to assess the impact of menopause, modeled as a time-varying covariate, on progressive disability milestones. Analyses were adjusted for age at MS onset, baseline disease duration, baseline EDSS score, baseline relapse, and exposure to high-efficacy disease-modifying therapy modeled as a time-varying covariate. MAIN OUTCOME MEASURES: In the primary analysis, the main outcome was time to 6-month confirmed disability progression (CDP). The secondary outcome was time to secondary progressive MS (SPMS). The secondary inflection point analysis examined longitudinal changes in EDSS in women who were followed up with throughout their menopausal transition. RESULTS: Primary analysis included 583 premenopausal and 404 postmenopausal women with MS. The median age at menopause was 48.5 years. Following multivariable adjustment, menopause was not associated with an increased risk of CDP or SPMS (hazard ratio, 0.95; 95% CI, 0.70-1.29; P = .70 and hazard ratio, 1.00; 95% CI, 0.60-1.67; P = 1.00), respectively. In the secondary analysis, menopause did not represent an inflection point in EDSS worsening following multivariable adjustment. CONCLUSIONS AND RELEVANCE: While reproductive aging may be additive to the effects of somatic aging, these results do not support menopause as the leading factor for disability progression in older women with MS.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Bridge F, Sanfilippo PG, Zhu C, et al. Menopause Impact on Multiple Sclerosis Disability Progression. JAMA Neurol. 2025. PMID: 41021242. doi:10.1001/jamaneurol.2025.3538

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。